Parkinson’s Disease Drug Pipeline Analysis Report 2024

According to the National Institute of Health, Parkinson's disease affects 1 to 2 people per 1000 individuals. The prevalence increases with age and affects 1% of the population aged 60 years and above. The condition is more common in males as compared to females. Major pharma companies and research institutes are developing and bringing new therapies, thereby, accelerating the drug pipeline significantly. 

Key Takeaway

• Major companies involved in the Parkinson’s disease pipeline drugs market include Bayer and Pfizer among others.

• Leading drugs currently under pipeline include Rotigotine and Azilect among others.

• Regulatory authorities such as the FDA and EMA play an essential role in the drug pipeline for Parkinson’s disease as they are offering breakthrough designations and fast-track approvals to several drugs, intended to provide effective treatment to patients having Parkinson’s disease.

Report Coverage

The Parkinson’s Disease Drug Pipeline Report by Expert Market Research gives comprehensive insights into Parkinson’s disease drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Parkinson’s disease. The report includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from Parkinson’s disease.

The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to Parkinson’s disease are covered.

Parkinson’s Disease Drug Pipeline Outlook

Parkinson's disease is a progressive disorder which affects the nervous system and other parts of the body controlled by the nerves. The disorder causes stiffness or slowed movement. The average age at which this condition starts is 60 years old and the condition progresses with age. The disease is very common and ranks as the second most common age-related degenerative brain disease. It is also the most common movement-related brain disease.

The symptoms of Parkinson’s disease vary for every individual and may include tremors, slowed movement (known as bradykinesia), impaired posture and balance, rigid muscles, loss of automatic movements and speech changes among others. The treatment for Parkinson’s disease includes medications and surgical procedures. The medications include carbidopa-levodopa, inhaled carbidopa-levodopa, carbidopa-levodopa infusion, dopamine agonists, monoamine oxidase B (MAO B) inhibitors, catechol O-methyltransferase (COMT) inhibitors, anticholinergics, amantadine, and adenosine receptor antagonists among others.

There are several unmet needs for patients. For instance, there is not an efficient treatment for motor symptoms such as levodopa-induced dyskinesia and imbalance. However, novel therapies which are currently in phase II and III trials are developing innovative treatments including the treatment of motor symptoms and are expected to revolutionize treatment for patients. Annovis Bio is currently in a phase III trial which is evaluating the efficacy, safety, and tolerability of DMT buntanetap tartrate. The mechanism of the drug involves inhibiting the production of neurotoxic proteins derived from the amyloid precursor protein (APP). The presence of large clinical trials for Parkinson’s disease is influencing the pipeline landscape significantly.

Parkinson’s Disease – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of Parkinson’s disease drugs based on several segmentations including:

By Phase

EMR’s pipeline assessment report covers 50+ drug analyses based on phase.

• Late-Stage Products (Phase 3 and Phase 4)

• Mid-Stage Products (Phase 2)

• Early-Stage Products (Phase I)

• Preclinical and Discovery Stage Products

By Drug Class

EMR’s pipeline assessment report covers 50+ drug analyses based on drug classes:

• Small Molecule

• Monoclonal Antibody

• Peptide

By Route of Administration

EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.

• Oral

• Parenteral

• Others

Parkinson’s Disease – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for Parkinson’s disease with 572 pipeline drugs in the respective phase.

Parkinson’s Disease – Pipeline Assessment Segmentation, By Drug Classes

The drug molecules categories covered under Parkinson’s disease pipeline analysis include small molecule, monoclonal antibody, and peptide. Prasinezumab is a monoclonal antibody which binds aggregated α-synuclein and is being investigated as a potential disease-modifying therapy for the treatment of early-stage Parkinson’s disease. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Parkinson's disease.

Parkinson’s Disease Clinical Trials Assessment – Competitive Dynamics

The EMR report for the Parkinson’s disease drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Parkinson’s disease clinical trials:

• Navidea Biopharmaceuticals

• CENTOGENE GmbH Rostock

• UCB Biopharma S.P.R.L.

• Chongqing Fortune Pharmaceutical Co., Ltd.

• Bayer

• Pfizer

• Zambon SpA

• Supernus Pharmaceuticals, Inc.

• Biotie Therapies Inc.

• Celavie Bioscences, LLC

• Taiwan Mitochondrion Applied Technology Co., Ltd.

• Amgen

• Others

Parkinson’s Disease – Pipeline Drugs Profile

Biological: Spheramine (BAY86-5280)

The trial is designed to evaluate the tolerability and efficacy of spheramine in patients with advanced Parkinson’s disease. The trial is sponsored by Bayer and is currently under phase II.

Drug: Liatermin (r-metHuGDNF)

The objective of the study is to evaluate the clinical safety and effectiveness of IPu-infused liatermin (15mg/putamen/day) in patients with symptomatic, levodopa-response Parkinson’s disease. The trial is sponsored by Amgen and is currently under phase I.

Drug: Rotigotine

UCB Pharma is developing the drug, and it is currently under phase III. The study is designed to demonstrate that Rotigotine transdermal patch is effective with advanced-stage idiopathic Parkinson’s disease as an adjuvant therapy.

Reasons To Buy This Report

The Parkinson’s Disease Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for Parkinson’s disease. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within Parkinson’s disease pipeline insights.

Key Questions Answered in the Parkinson’s Disease – Pipeline Assessment Report

• What is the current landscape of Parkinson’s disease pipeline drugs?
• How many companies are developing Parkinson’s disease drugs?
• How many phase III and phase IV drugs are currently present in Parkinson’s disease pipeline drugs?
• Which companies/institutions are leading the Parkinson’s disease drug development?
• What is the efficacy and safety profile of Parkinson’s disease pipeline drugs?
• What are the opportunities and challenges present in the Parkinson’s disease drug pipeline landscape?
• Which company is conducting major trials for Parkinson’s disease drugs?
• What are the geographies covered for clinical trials in Parkinson’s disease?
• What are emerging trends in Parkinson’s disease clinical trials?

Related Reports

Parkinson’s Disease Drugs Market

Brain Tumor Treatment Market

Neurodiagnostic and Monitoring Devices Market